Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Rottapharm Biotech
Private Company Edition: Amylyx will use its new cash to run a Phase III trial and submit applications seeking EU and Canadian approvals of AMX0035, but US filing plans based on prior Phase II/III data are less clear. Also, three VC firms raised new funds targeting biopharma and other investments.
The WHO indicates that several claim applications have been made under the COVAX no-fault lump-sum compensation program for COVID-19 vaccines. It remains to be seen how the scheme may apply to countries like India, which is also expected to take a call on indemnity to vaccine makers.
A plasmid DNA vaccine for human use has moved a step closer to reality, with Zydus Cadila applying for an accelerated nod for its COVID-19 candidate in India. 67% efficacy reported in an interim data readout and Delta variant being the prominent strain during a Phase III trial imply better odds for approval.
Becton Dickinson claims Beckman Coulter has been knowingly violating several patents since at least 2015.
- OTC, Consumer
- Other Names / Subsidiaries
- Madaus Pharma
- Rottapharm Madaus